Novo Nordisk Revises 2025 Outlook as FDA Crackdown and Competition Reshape Wegovy Market

The Danish drugmaker expects U.S. Wegovy sales to recover in H2 2025 following FDA enforcement and a new CVS formulary deal, despite lowering growth forecasts due to compounding competition.